In 2014, a mid-sized contract manufacturer in Gujarat won a bid to produce a generic Sitagliptin intermediate for an EU pharmaceutical customer. The process required a ring-closing metathesis step that had been run successfully for two years with their existing catalyst supply. Three months into the new contract, the yield on that step dropped from 87% to 51%. The supplier swore nothing had changed. The QC manager eventually discovered the lot-to-lot variation in the ruthenium catalyst’s residual phosphine content was throwing off the initiation kinetics — the previous batches had coincidentally been lower in phosphine, and the process had never been properly optimized around that impurity window. That discovery cost the company four weeks of downtime, a rejected batch, and a €40,000 revalidation exercise. It illustrates why sourcing Grubbs Catalyst 2nd Generation with tight phosphine specification matters more than sourcing on price alone.